Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 28, 2015
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the...
- Jul 16, 2015Deal Supports Strategic Directions of Both Companies and Expands Collaboration
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP)...
-
Jun 22, 2015New Indication Provides a Treatment Option for Epilepsy Patients Who Suffer from PGTC Seizures that are not Adequately Controlled with Current Treatment
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic...
- Jun 1, 2015
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Ivor Macleod to the position of Senior Vice President, Chief Financial Officer (CFO)...
-
Jun 1, 2015Lenvatinib, investigated in patients with metastatic renal cancer, showed an increase in progression-free survival (PFS)
Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival...
-
May 30, 2015Data from pivotal study for eribulin to be presented during oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced...
-
May 14, 2015Company demonstrates dedication to rare cancers
Eisai Inc. announced today the presentation of seven abstracts at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) highlighting the breadth of the company's oncology...
-
Apr 30, 2015
Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and Glenmark Generics, Inc., USA ("Glenmark"), to resolve their...
-
Apr 15, 2015
Helsinn Group and Eisai Inc. jointly announced today the decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 NCCN Antiemesis Guidelines as a recommended...
- Apr 13, 2015-- Data to Highlight Impact of H3's Splicing Modulation Platform --
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today that it will present a series of posters at the...
-
Apr 10, 2015-- New Drug Application for once-daily formulation of lorcaserin expected to be submitted to the FDA later this year --
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, April 10, 2015 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials...
-
Apr 9, 2015
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by...
-
Mar 30, 2015Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of farletuzumab in first-relapsed, platinum-sensitive...
- Feb 27, 2015A New Drug Approved for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that LENVIMA™ (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty pharmacies, Accredo and Biologics, Inc. LENVIMA is indicated...
-
Feb 25, 2015Eisai Demonstrates Commitment to Patients with Rare Cancers
Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial (Study 309), demonstrating a statistically significant improvement in overall survival (OS) in patients with...
-
Feb 19, 2015
Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with obesity. Meant to inspire and encourage honest, open...
-
Feb 13, 2015- New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor LENVIMA™ (lenvatinib) for the treatment of locally recurrent...
- Feb 13, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for BANZEL® (rufinamide) as an adjunctive treatment of seizures...
-
Feb 12, 2015FOR U.S. MEDIA ONLY
Results from the pivotal Phase 3 SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of...
- Jan 20, 2015Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIVCard Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*
Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.**...
-
Jan 15, 2015•The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
Paris, January 15, 2015 – The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the...
- Dec 5, 2014-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --
Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...
-
Dec 1, 2014FOR U.S. MEDIA ONLY
Eisai announced the presentation of six abstracts at the 2014 San Antonio Breast Cancer Symposium (SABCS), highlighting new data for eribulin mesylate and netupitant/palonosetron (NEPA). The...
-
Nov 17, 2014
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index...
- Nov 6, 2014Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support
Eisai Inc. today announced the launch of Magnolia™ Paws for Compassion™, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy...
